Deslorelin (Suprelorin), manufactured in Australia by Virbac is an anti-androgenic hormone (GnRH agonist) used as an off-label treatment for prostatic hyperplasia in dogs and esrus induction in bitches.
Deslorelin was initially developed in Australia as an ovulation-inducing agent in mares.
Deslorelin effects contraception by temporarily suppressing the reproductive endocrine system, preventing production of pituitary (FSH and LH) and gonadal hormones (estradiol and progesterone in females and testosterone in males).
Implanted deslorelin appears active in suppressing the function of the pituitary-gonadal axis and thus sexual activity for 8-12 months, although longer periods of anoestrus have been reported. Unlike other GnRH agonists, which are mainly used to inhibit luteinizing hormone and follicle-stimulating hormone by their ultimate down-regulation of the pituitary gland, Deslorelin is primarily used for the initial flare effect upon the pituitary, and its associated surge of LH secretion.
Few side-effects have been reported with this drug
Deslorelin is available as a single 4.7 mg bio-compatible implant for use in cats. A single implant is injected subcutaneously. Although most veterinarians implant the device in the periscapular region (scruff), it is recommended to implant the device in the inguinal area (preferably a glabrous region) should the device need to be removed at a later date.
Repeated implant use may be efficacious in case which respond to therapy but no long-term studies have been reported about multiple use in felines.
The implant is difficult to remove if reversal is desired before the hormone in the implant becomes depleted, since the implant breaks easily. However, careful implant insertion to avoid breakage can facilitate later removal.
- Palm J & Reichler IM (2012) The use of deslorelin acetate (Suprelorin®) in companion animal medicine. Schweiz Arch Tierheilkd 154(1):7-12
- Fontaine E et al (2011) Induction of fertile oestrus in the bitch using Deslorelin, a GnRH agonist. Theriogenology 76(8):1561-1566
- Trigg T.E., et al (2006) A review of advances in the use of the GnRH agonist deslorelin in control of reproduction. Theriogenology 66:1507-1512